- Home
- PWM vs EDSA Comparison
PWM vs EDSA Comparison
Compare PWM & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWM
- EDSA
- Stock Information
- Founded
- PWM 2018
- EDSA 2015
- Country
- PWM Hong Kong
- EDSA Canada
- Employees
- PWM N/A
- EDSA N/A
- Industry
- PWM
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- PWM
- EDSA Health Care
- Exchange
- PWM Nasdaq
- EDSA Nasdaq
- Market Cap
- PWM 12.4M
- EDSA 13.8M
- IPO Year
- PWM 2023
- EDSA N/A
- Fundamental
- Price
- PWM $0.35
- EDSA $2.03
- Analyst Decision
- PWM
- EDSA Strong Buy
- Analyst Count
- PWM 0
- EDSA 2
- Target Price
- PWM N/A
- EDSA $13.00
- AVG Volume (30 Days)
- PWM 180.3K
- EDSA 33.4K
- Earning Date
- PWM 07-07-2025
- EDSA 08-08-2025
- Dividend Yield
- PWM N/A
- EDSA N/A
- EPS Growth
- PWM N/A
- EDSA N/A
- EPS
- PWM N/A
- EDSA N/A
- Revenue
- PWM $639,912.00
- EDSA N/A
- Revenue This Year
- PWM N/A
- EDSA N/A
- Revenue Next Year
- PWM N/A
- EDSA N/A
- P/E Ratio
- PWM N/A
- EDSA N/A
- Revenue Growth
- PWM 83.60
- EDSA N/A
- 52 Week Low
- PWM $0.31
- EDSA $1.55
- 52 Week High
- PWM $2.70
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- PWM 42.41
- EDSA 52.89
- Support Level
- PWM $0.33
- EDSA $1.91
- Resistance Level
- PWM $0.37
- EDSA $2.14
- Average True Range (ATR)
- PWM 0.03
- EDSA 0.12
- MACD
- PWM -0.00
- EDSA 0.02
- Stochastic Oscillator
- PWM 28.75
- EDSA 64.52
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.